Medical/Pharmaceuticals
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...
2025-03-24 21:00
1621
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
2212
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...
2025-03-24 20:00
3307
Fangzhou Inc. Reports Strong Growth in 2024 Annual Results: 11.2% Revenue Growth and 139% Year-on-Year Increase in Adjusted Net Profit Driven by AI-Powered Innovation
HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue ofRMB 2.7 billion, representing an 11.2% year-over-year inc...
2025-03-24 11:00
3040
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...
2025-03-24 08:15
2322
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...
2025-03-24 07:56
2174
Aphranel® MagiCCrystal CaHA Filler from Shanghai MOYOM Biotec, Obtains NMPA Class III Medical Device Certificate in China
——The World's First Precisely Regulated Injectable CaHA Filler, Accelerating Compliance in the Medical Aesthetics Industry inChina. SHANGHAI, March 21, 2025 /PRNewswire/ -- Shanghai Moyom Biotechnology's high-profile brand,Aphranel® MagiCCrystal CaHA Filler, has officially obtained Class III Med...
2025-03-21 21:00
4227
Syneron Bio Announces Strategic Collaboration with AstraZeneca
BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...
2025-03-21 20:02
2469
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global ...
2025-03-21 19:21
2491
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific ...
2025-03-21 11:14
2212
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-03-21 08:30
1979
Wounds hard to heal? Troubled by dressing changes? Dimora, Amazon's 3-year top brand, shows you the way.
NEW YORK, March 20, 2025 /PRNewswire/ -- Dimora Medical
2025-03-21 01:08
2030
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025
* Company Joins NVIDIA Healthcare & Life Sciences (HCLS) Ecosystem to Advance Global Diagnostic Accessibility and Seeks Partnerships with Global Healthcare Opportunities YONGIN, South Korea, March 20, 2025 /PRNewswire/ -- Noul Co., Ltd. a Korea-based medical AI company, announced that it presen...
2025-03-21 00:00
3153
Seegene Unveils HPV Genotyping Solution at EUROGIN 2025
- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held inPortugal from March 16-19 - Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals SEOUL, South K...
2025-03-20 21:00
2108
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing th...
2025-03-20 21:00
2227
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) inChina SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmace...
2025-03-20 20:00
1919
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL * The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmac...
2025-03-20 18:00
1859
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
* Achieved First-Ever Annual Operating Profit * Bottom Line Improved by RMB332.7 Million YoY in 2024 * Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 * Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY * Achieved Fi...
2025-03-20 13:00
3872
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development
CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology ...
2025-03-19 22:00
2164
Jacobio Pharma Announces 2024 Annual Results
BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense ofRMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank b...
2025-03-19 21:42
4072
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
7665
